A randomized phase 3b study evaluating safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement

This IMMprint study aimed to evaluate the safety and efficacy of risankizumab (RZB) compared to a placebo for the treatment of non pustular palmoplantar psoriasis (PPPsO). The study involved randomizing patients to receive either RZB or placebo for 16 weeks, followed by continued RZB treatment until week 52. RZB showed significant efficacy compared to the placebo at week 16 in terms of achieving clear or almost clear skin, improvement in the severity of palmoplantar psoriasis, and improved physician assessment. The results continued to improve through week 52, and no new safety concerns were identified. However, the study did not compare RZB to other biologic treatments. In conclusion, RZB demonstrated both safety and efficacy for the treatment of PPPsO.

本IMMprint研究旨在评估瑞莎珠单抗（risankizumab，RZB）对比安慰剂治疗非脓疱性掌跖银屑病（non pustular palmoplantar psoriasis，PPPsO）的安全性与有效性。该研究将患者随机分配至RZB组或安慰剂组，接受为期16周的治疗，后续持续接受RZB治疗直至第52周。在第16周时，相较于安慰剂组，RZB组在实现皮肤完全或几乎完全清除、掌跖银屑病严重程度改善以及医师评估结果改善方面均展现出显著疗效。其疗效在第52周时仍持续提升，且未发现新的安全性信号。不过，本研究未将RZB与其他生物制剂治疗方案进行对照。综上，RZB在治疗PPPsO方面兼具安全性与有效性。